OMRON-HEALTHCARE
OMRON Healthcare , Inc., the global leader in remote blood pressure monitoring and personal health technology, spotlighted its new remote patient monitoring services at the 2022 Consumer Electronics Show (CES) and won “Best of” honors for its offerings in the U.K. and U.S:
- Hypertension Plus by OMRON in the U.K. was selected as a TWICE Picks Awards winner for the 2022 TWICE , Residential Systems and TechRadar Pro Picks Awards
- VitalSight™ by OMRON in the U.S. was recognised as an INSIDER “Best of” CES selection
These remote patient monitoring services gained recognition at the world’s largest innovation show as breakthrough health technology designed to foster greater active health condition management, strengthen the patient-physician connection, and guide behavior change to reduce health risks, while advancing the company’s mission of Going for Zero heart attacks and strokes.
“OMRON developed Hypertension Plus as the first step toward transforming chronic care in the U.K., while VitalSight was designed to help the 37 million Americans who have uncontrolled Stage 2 hypertension and live every day with a higher risk of heart attack and stroke,” said Andre Van Gils, senior general manager, global sales & marketing and executive officer of OMRON Healthcare Corporation Ltd. - Japan.
Hypertension Plus is designed to help NHS clinicians manage a patient’s medication plan remotely, based on the patient’s home blood pressure results submitted through its dedicated mobile app. The platform generates tailored medication plans for patients, which are then adjusted by clinicians as necessary. Patients are then informed immediately over the dedicated mobile app, connecting them directly to their physician. Automated reminders and scheduled condition management actions keep the patient engaged in treatment. Over time, Hypertension Plus collates the patient’s blood pressure readings along with other key health parameters and informs clinicians when it’s time for their patients to progress in their treatment plan or if there is any urgent action to be taken. All of these recommendations are underpinned by an exclusive algorithm founded on clinically proven medication titration techniques for hypertension, based on current National Institute for Health and Care Excellence (NICE) guidelines, and developed by Oxford university.
In addition to CES, Hypertension Plus has also been recognised by ORCHA (the Organisation for the Review of Care and Health Applications) and Dorset Clinical Commission Group (CCG) on their leading UK-recognised health and care app review portal, with Hypertension Plus currently the highest rated application for hypertension.
In their annual rankings, TWICE, Residential Systems , and TechRadar Pro Picks Awards honor the best and most influential consumer technology. The TWICE Picks Awards Winners 2022 were chosen based on the impact that they are expected to have on the consumer electronic and retail Industries. To see the full list, visit TWICE , Residential Systems or TechRadar Pro .
VitalSight is the first remote patient monitoring service from OMRON Healthcare, an easy-to-use service that a physician can offer to patients with high-risk levels of hypertension. Patients receive a kit delivered to their home that includes an OMRON connected blood pressure monitor and data hub that are pre-set to securely share measurements – digitally – with the patient’s physician and care team. The VitalSight data hub, which can be used at home without Wi-Fi or cellular connection, received attention at CES for bridging health care gaps for patients in under-resourced communities.
Insider recognised VitalSight by OMRON on its list of 13 most exciting health, home and kitchen products of CES 2022. The list brought together high-tech concepts and new products – unveiled at CES 2022 – that you can buy now or later in 2022. Insider cited VitalSight among the “Best of” CES as “life-saving technology” and “great technology for patients who can't see their doctor regularly because of location, finances, or mobility concerns.” To see the full list, visit Insider.
“Our team, fully committed to our Going for Zero mission, worked diligently to create and launch our remote patient monitoring services around the world,” said Van Gils. “We are fortunate to have such dedicated staff and employees who are passionate about empowering people to take charge of their heart health and saving lives. Congratulations to our team on this extraordinary effort.”
To learn more about Remote Patient Monitoring services from OMRON, visit: https://healthcare.omron.com/ces2022
To learn more about OMRON Healthcare, the company’s Going for Zero mission and its innovations, visit omron-healthcare.co.uk , and follow OMRON Healthcare on Twitter and LinkedIn.
About OMRON Healthcare
Committed to helping people live more active and fulfilling lives with zero compromise, OMRON Healthcare is a global leader in the field of clinically proven, innovative medical equipment for health monitoring and therapy.
Throughout its 85-year history OMRON Healthcare has been striving to improve lives and contribute to a better society by developing innovations that help people prevent, treat and manage their medical conditions, both at home and in clinical practice in over 117 countries.
OMRON Healthcare is the Global No.1 brand in both blood pressure monitors, with over 200 million units sold, as well as nebulizers for respiratory treatment with over 30 million devices sold. The company’s additional core product categories are low-frequency pain therapy equipment, body composition monitors and electronic thermometers.
OMRON Healthcare Group is headquartered in Kyoto, Japan. OMRON Healthcare Europe B.V. is the healthcare division for Europe, Russia, Middle East and Africa and provides services to customers in more than 74 countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220121005268/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Opens up New Chapter for Sculptra® with MDR Certification and New Expanded Indication for Body5.12.2025 07:00:00 CET | Press release
Sculptra®, the first proven regenerative biostimulator, has received European Union (EU) Medical Device Regulation (MDR) certification, expanding its current clinical application for the face to include gluteal area, posterior thighs, décolletage, and upper arms1 Studies investigating the efficacy of Sculptra on areas beyond the face show patients experienced progressive improvements in skin quality (including the improvement in cellulite appearance), firmness, lift, projection, and contour Sculptra’s versatility and new indication allow practitioners to shift patient treatment goals beyond rejuvenation toward enhancement, meeting evolving patient needs The certification validates Sculptra’s safety performance, efficacy, and quality, reinforcing Galderma’s commitment to innovation and meeting evolving patient needs Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the certification of Sculptra for body indications in the European Union (EU) following its
Northern Escape Heli-Skiing Takes the Title of “World’s Best Heli-Ski-Operator” for the 4th Year Running5.12.2025 02:40:00 CET | Press release
4x World’s Best Heli-Skiing Operation near Terrace, BC Northern Escape Heli-Skiing (NEH) has been named World’s Best Heli-Ski Operator 2025 by the World Ski Awards, marking its fourth straight victory following years 2022, 2023 and 2024. This recognition places NEH amongst an elite group of ski tourism operators consistently voted best in the world by industry leaders and enthusiasts alike. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204074550/en/ A four-year run built on reliability NEH operates in British Columbia’s Skeena Mountains, where deep northern snow and vast terrain come together with small-group heli-skiing and heli snowboarding. When helicopters can’t safely fly, NEH has cat skiing readily available as a backup — an exceedingly rare offering in this industry. The operation spans over 833,571 wild acres of alpine bowls, glaciers and old-growth tree skiing. The NEH experience Guests choose from three lodge f
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance5.12.2025 01:00:00 CET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific antibody-drug conjugate (ADC). IDEAYA expects to begin patient enrollment in Q1 2026, initially evaluating patients with solid tumors known to express B7H3 and PTK7, including lung, colorectal, head and neck, and ovarian/gynecological cancers. IDE034 is a bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and licensed to IDEAYA in July 2024. The IND clearance marks an important milestone for this licensed program, supporting subsequent clinical development of IDE034, while highlighting Biocytogen’s technical capabilities in bispecific ADC discovery and development. Dr. Yue
Helical Fusion, Developer of Next-Generation Clean Energy Through Nuclear Fusion, Completes USD 5.5M Series A Extension Round5.12.2025 01:00:00 CET | Press release
Stakeholder base expands with participation from an individual-investor-oriented fund, alongside corporate and individual investors, bringing Total Funding to USD 38M Helical Fusion Co., Ltd. (Head Office: Chuo-ku, Tokyo; CEO: Takaya Taguchi; hereafter “Helical Fusion”), which is developing a next-generation energy source using Japan’s original Helical Stellarator technology to realize commercially viable fusion power plant in the 2030s, announced the completion of its Series A Extension round, raising approximately USD 5.5 million (≈ JPY 870 million). The round included investments from “Ecrowd NEXT”, a fund designed for individual investors, as well as multiple corporate investors and individual investors. As a result, Helical Fusion’s total Series A funding, including loans, amounts to approximately USD 21 million (≈ JPY 3.2 billion), bringing the company’s cumulative fundraising—including grants and loans—to approximately USD 38 million (≈ JPY 6.0 billion). With this funding, Helic
Andersen Consulting udvider sin tilstedeværelse gennem samarbejde med Hilal Technology4.12.2025 23:04:00 CET | Pressemeddelelse
Andersen Consulting indgår en samarbejdsaftale med Hilal Technology for at styrke sine kompetencer inden for digital infrastruktur, cybersikkerhed og AI. Med tilstedeværelse i Bahrain, Saudi-Arabien, De Forenede Arabiske Emirater, Oman og Indien leverer Hilal Technology et komplet spektrum af digital infrastruktur og managed services inden for cloudcomputing, cybersikkerhed, enterprise ai og systemintegration. Deres ydelser omfatter cloudtjenester, sikkerheds- og netværksdrift, implementering af ERP og applikationer samt udvikling af generative ai-kapaciteter. Med et team på mere end 250 fagfolk servicerer firmaet en bred vifte af brancher, herunder den finansielle sektor, olie og gas, logistik og den offentlige sektor. "Transformation er mere end systemer; det handler om parathed, tillid og løbende samarbejde," udtaler Roshan George, direktør for Hilal Technology. "Vi er begejstrede for at samarbejde med Andersen Consulting og levere skalerbare løsninger, der matcher tempoet i den dig
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom